Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the clinical trial application for 9MW3911 Injection independently developed by its subsidiary Nanjing NovoAcine Biotechnology Co., Ltd. was accepted by National Medical Products Administration (NMPA) for the indication of advanced malignancies.

9MW3911 is a non-IL-2 blocking CD25 monoclonal antibody with independent intellectual property rights developed by a highly effective Single B Cell Screening Platform. This product selectively removes CD25-overexpressing regulatory T cells (Treg) mainly through antibody-dependent cell-mediated cytotoxicity (ADCC) without blocking IL-2 signaling pathway, thus modulates tumor microenvironment and enhances tumor immunity. Pre-clinical studies showed that 9MW3911 had good in vivo anti-tumor efficacy and good tolerability in animals.